Prognostic impact of prior local therapy in castration-resistant prostate cancer

Mikifumi Koura, Masaki Shiota, Shohei Ueda, Takashi Matsumoto, Satoshi Kobayashi, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken Ichiro Shiga, Akira Yokomizo, Masatoshi Eto

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: This study aimed to reveal the prognostic values of prior local therapy in first-line therapy using androgen receptor-axis targeting agents (abiraterone or enzalutamide) or docetaxel for castration-resistant prostate cancer (CRPC). Methods: The study included 303 patients treated with first-line therapy for non-metastatic and metastatic CRPC. The association between prior local therapy and therapeutic outcome including progression-free survival and overall survival was investigated by univariate and multivariate analyses as well as propensity score-matched analysis. Results: In univariate analysis, local prior therapy was associated with a lower risk of all-cause mortality (hazard ratio, 0.56, 95% confidence interval, 0.40-0.79; P = 0.0009). Overall survival, but not progression-free survival, was better among patients with prior local therapy compared with patients without prior local therapy even after multivariate analysis and propensity score-matched analysis. Conclusions: This study robustly indicated that prior local treatment was prognostic for overall survival among patients with CRPC. This finding is useful to predict patient prognosis in CRPC.

Original languageEnglish
Pages (from-to)1142-1148
Number of pages7
JournalJapanese journal of clinical oncology
Volume51
Issue number7
DOIs
Publication statusPublished - Jul 1 2021

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Prognostic impact of prior local therapy in castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this